AstraZeneca to strengthen therapy area franchise through acquisition of Takeda’s respiratory business
Acquisition to include non-US rights to roflumilast and will beaccretive to 2016 earnings, contributing to AstraZeneca’s return to growth strategy
Ämnen: Industri, tillverkning
-
-
Discussions with Acerta Pharma BV
Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, inn -
AstraZeneca i samarbete med nytt svenskt center för proteinforskning för utveckling av nästa generations läkemedel genom sekretomforskning
AstraZeneca och koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, Medimmune, meddelar idag ett treårigt samarbete med det nybildade forskningscentret Wallenberg Centre for Protein Research (WCPR).
-
AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015
-
AstraZeneca and Sanofi exchange over 200,000 chemical compounds
AstraZeneca and Sanofi today announced a direct exchange of 210,000 compounds from their respective proprietary compound libraries. The swap represents a novel open innovation model between pharmaceutical companies.
-
AstraZeneca expands technological investment in new Cambridge lead discovery centre
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical
-
Tagrisso™ (AZD9291) approved by the US FDA for patients with EGFR t790m mutation-positive metastatic non-small cell lung cancer
One of fastest development programmes – from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate of 59% and duration of response of 12.4 months, TAGRISSO provides important new option for patients
-
Outtröttlig bröstcancerkämpe får prestigetyngd utmärkelse
BRO:s Utmärkelse 2015 tilldelas Helena Janlöv-Remnerud, sjuksköterska och medicinsk lymfterapeut, hemmahörande i Edsbro i Uppland.
-
PEGASUS-TIMI 54 SUB-ANALYSIS OUTLINES LONG-TERM TOLERABILITY DATA FOR BRILIQUE
Data presented at AHA suggests benefit in patients who stayed on Brilique (ticagrelor) treatment.
-
AstraZeneca presents positive new data on anifrolumab in lupus at American College of Rheumatology Annual Scientific Meeting
Anifrolumab met primary and secondary endpoints in Phase II, significantly reducing lupus disease activity compared with placebo across multiple endpoints
-
AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma
AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review
-
Delårsrapport AstraZeneca PLC för de första nio månaderna och tredje kvartalet 2015
Pascal Soriot, koncernchef, kommenterar resultatet: "Jag är nöjd med framstegen vi gör. Vi fortsätter att fokusera på genomförandet av våra planer för tillväxtplattformarna och forskningsportföljen.
-
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
AstraZeneca and Eli Lilly and Company (Lilly) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumours
-
AstraZeneca opens new manufacturing facility to support continued growth in Russia
AstraZeneca today announced the opening of its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
-
Losec nu tillgängligt i matbutiker
Läkemedelsverket har godkänt försäljning av Losec (omeprazol), ett läkemedel mot refluxsjukdom i svensk dagligvaruhandel. Det receptfria läkemedlet kommer att finnas tillgängligt på COOP, Willys, Hemköp och MatHem, samt på vissa bensinstationer runt om i landet.Losec är ett svenskt läkemedel som forskades fram av AstraZeneca i Göteborg.
-
AstraZeneca receives complete response letter from US FDA for saxagliptin / dapagliflozin fixed-dose-combination
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for the investigational fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adult patients with type 2 diabetes
-
Grymt Fett – AstraZenecas filmserie om tonårshjärnan – en succé i svenska skolor
AstraZenecas filmserie ”Grymt Fett” - om hur tonårshjärnan fungerar har blivit en succé i svenska skolor. Filmerna är det mest beställda materialet av lärare från beställningstjänsten Utbudet och har setts av fler än 250 000 elever.
-
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies – AMAGINE-2 and AMAGINE-3 - demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.
-
Moventig in i högkostnadsskyddet
Tandvårds- och läkeförmånsnämnden har beslutat att AstraZenecas läkemedel Moventig® (naloxegol) nu ingår i läkemedelsförmånen endast för patienter med opioidorsakad förstoppning med otillräckligt behandlingssvar på laxermedel. Det innebär att subvention ges i enlighet med läkemedlets godkända indikation.
-
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and lynparza™ (olaparib)
AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership in oncology, at the European Cancer Congress (ECC) 2015 in Vienna, Austria (25-29 September 2015).
Visa mer
Loading...